Netherton Syndrome Market
Netherton syndrome is a rare disorder identified by trichorrhexis invaginata, atopic diathesis, and ichthyosiform erythroderma. It is hereditary as it is an autosomal recessive trait. The disease is majorly caused due to mutations associated with SPINK5 gene. In some cases, the syndrome also develops when two healthy parents with no family history of the disease but with the mutated recessive gene give birth to a child who receives both copies of the recessive gene. Netherton syndrome market is expected to reach US$ 74.31 million by 2027 from US$ 19.57 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2021 to 2030.
Market Drivers
Market is witnessing major growth due to the increasing awareness regarding Netherton syndrome and growing number of product introductions. Awareness campaigns are being considered to be helpful in means of enabling timely and accurate diagnosis as well as social and various medical organizations are working towards spreading awareness. Moreover, rising number of clinical trials and robust pipeline of products act as significant opportunities for the future growth of the market players.
Market Restraints
However, the risk of adverse reactions associated with the Netherton syndrome treatment drugs restrains the growth of the market. Through which people will stop with awareness campaigns which will affect various organizations.
Market Segmentation
Globally market is segmented on the basis of therapy. By therapy, market is segmented into keratolytic agents, oral and topical steroids and retinoid, topical calcineurin inhibitors, biological therapies, and radiation therapies. The biological therapy segment is estimated to register the highest CAGR in the market during the forecast period. Market growth for the biological therapy segment is assigned to the increasing adoption of biological therapy due to its beneficial treatment outcomes whereas the growth of keratolytic segment is attributed to the increased product launches and robust existing product pipeline.
Regional Analysis
COVID-19 recovery and resuming the healthcare improvement journey will be at the forefront of 2021 healthcare trends in Asia-Pacific (APAC) countries such as India, China, and Japan, as they are around the world. However, the APAC region's combination of industrialized and developing countries presents distinct issues, as healthcare access and basic infrastructure differ significantly between urban and rural populations and economic levels
Key Players
Lifemax Laboratories, Inc.; Azitra, Inc.; Sixera Pharma Ab; Dermelix Biotherapeutics; Matrisys Bioscience; Quoin Pharmaceuticals Ltd.; and Krystal Biotech, Inc. are a few of the leading companies operating in the Netherton syndrome market.
Industry development
Netherton Syndrome Market Segmentation
By Therapy
By Region
Key Questions Addressed by the Report?
Global Netherton Syndrome Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Netherton Syndrome Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
5 Global Netherton Syndrome Market, By Therapy
5.1 Y-o-Y Growth Comparison, By Therapy
5.2 Global Netherton Syndrome Market Share Analysis, By Therapy
5.3 Global Netherton Syndrome Market Size and Forecast, By Therapy
5.3.1 Keratolytic agents
5.3.2. Oral and Topical Steroids and Retinoid
5.3.3. Topical Calcineurin Inhibitors
5.3.4. Radiation Therapies
5.3.5. Biological Therapies
6. Global Netherton Syndrome Market, By Region
7.1 Global Netherton Syndrome Market Share Analysis, By Region
7.2 Global Netherton Syndrome Market Share Analysis, By Region
7.3 Global Netherton Syndrome Market Size and Forecast, By Region
8. North America Netherton Syndrome Market Analysis and Forecast (2021-2030)
8.1 Introduction
8.2 North America Netherton Syndrome Market Share Analysis, By Therapy
8.5 North America Netherton Syndrome Market Size and Forecast, By Country
8.5.1 U.S.
8.5.2 Canada
8.5.3 Mexico
9. Europe Netherton Syndrome Market Analysis and Forecast (2021-2030)
9.1 Introduction
9.2 Europe Netherton Syndrome Market Share Analysis, By Therapy
9.5 Europe Netherton Syndrome Market Size and Forecast, By Country
9.5.1 Germany
9.5.2 France
9.5.3 UK
9.54. Rest of Europe
10. Asia Pacific Netherton Syndrome Market Analysis and Forecast (2021-2030)
10.1 Introduction
10.2 Asia Pacific Netherton Syndrome Market Share Analysis, By Therapy
10.5 Asia Pacific Netherton Syndrome Market Size and Forecast, By Country
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4. Rest of Asia Pacific
11. Latin America Netherton Syndrome Market Analysis and Forecast (2021-2030)
11.1 Introduction
11.2 Latin America Netherton Syndrome Market Share Analysis, By Therapy
11.5 Latin America Netherton Syndrome Market Size and Forecast, Country
11.5.1. Brazil
11.5.2. Rest of Latin America
12. Middle East Netherton Syndrome Market Analysis and Forecast (2021-2030)
12.1 Introduction
12.2 Middle East Netherton Syndrome Market Share Analysis, By Therapy
12.5 Middle East Netherton Syndrome Market Size and Forecast, By Country
12.5.1. Saudi Arabia
12.5.2. UAE
12.5.3. Egypt
12.5.4. Kuwait
12.5.5. South Africa
13 Competitive Analysis
13.1 Competition Dashboard
13.2 Market share Analysis of Top Vendors
13.3 Key Development Strategies
14 Company Profiles
14.1 Lifemax Laboratories,Inc
14.1.1 Overview
14.1.2 Offerings
14.1.3 Key Financials
14.1.4 Business Segment & Geographic Overview
14.1.5 Key Market Developments
14.1.6 Key Strategies
14.2. Azitra, Inc
14.2.1 Overview
14.2.2 Offerings
14.2.3 Key Financials
14.2.4 Business Segment & Geographic Overview
14.2.5 Key Market Developments
14.2.6 Key Strategies
14.3. Sixera Pharma Ab
14.3.1 Overview
14.3.2 Offerings
14.3.3 Key Financials
14.3.4 Business Segment & Geographic Overview
14.3.5 Key Market Developments
14.3.6 Key Strategies
14.4 Dermelix Biotherapeutics
14.4.1 Overview
14.4.2 Offerings
14.4.3 Key Financials
14.4.4 Business Segment & Geographic Overview
14.4.5 Key Market Developments
14.4.6 Key Strategies
14.5 Matrisys Bioscience
14.5.1 Overview
14.5.2 Offerings
14.5.3 Key Financials
14.5.4 Business Segment & Geographic Overview
14.5.5 Key Market Developments
14.5.6 Key Strategies
14.6 Quoin Pharmaceuticals Ltd
14.6.1 Overview
14.6.2 Offerings
14.6.3 Key Financials
14.6.4 Business Segment & Geographic Overview
14.6.5 Key Market Developments
14.6.6 Key Strategies
14.7 Krystal Biotech, Inc
14.7.1 Overview
14.7.2 Offerings
14.7.3 Key Financials
14.7.4 Business Segment & Geographic Overview
14.7.5 Key Market Developments
